New fatty liver drug enters early human testing
NCT ID NCT07407634
First seen Feb 14, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This early-phase study tests a new drug called XTYW007 in 94 healthy volunteers and people with high LDL cholesterol. The main goal is to check safety and how the drug moves through the body, with a first look at its effect on blood fats. It is not yet recruiting and aims to gather basic information for future development.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Hospital of Jilin University
Jilin, Changchun, China
Conditions
Explore the condition pages connected to this study.